Table 4.
HCV peptide antigenic pattern in HCV infected patients
| Serum | HCV peptide | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C1 | C2 | C3 | ||||||||||
| None | – | – | – | 0.27 | – | – | 0.35 | 0.39 | – | – | – | 0.21 |
| Healthy | ||||||||||||
| 1 | – | 0.23 | – | 0.52 | – | – | 0.33 | 0.29 | – | – | – | 0.49 |
| 2 | – | – | – | 0.39 | – | – | 0.24 | 0.30 | – | 0.27 | 0.33 | 0.28 |
| 3 | – | 0.23 | – | 0.48 | – | – | 0.73 | 0.45 | 0.22 | 0.21 | 0.24 | 0.66 |
| 4 | 0.22 | – | – | 0.25 | – | – | 0.44 | 0.28 | – | – | – | 0.94 |
| 5 | – | – | – | 0.30 | – | – | 0.53 | 0.30 | – | – | – | 0.62 |
| Blood donor | ||||||||||||
| 1 | – | 0.22 | – | 0.36 | – | – | 0.34 | – | – | – | – | 0.33 |
| 2 | – | 0.27 | 0.24 | 0.38 | – | – | 0.42 | 0.23 | – | – | – | – |
| 3 | – | – | – | 0.37 | – | – | 0.69 | 0.50 | 0.27 | – | – | 0.48 |
| 4 | – | – | – | 0.35 | – | – | 0.42 | – | – | – | – | 0.64 |
| 5 | – | – | – | 0.21 | – | – | 0.49 | 0.47 | – | – | – | 0.71 |
| 6 | – | – | – | 0.48 | – | – | 0.22 | 0.39 | – | – | – | 0.48 |
| 7 | – | – | – | – | – | – | 0.53 | 0.27 | 0.22 | 0.22 | 0.31 | 0.33 |
| 8 | – | – | – | – | – | – | 0.88 | 0.38 | 0.44 | – | – | 0.73 |
| 9 | 0.21 | – | – | – | – | – | 0.39 | 0.50 | – | – | 0.27 | 0.59 |
| 10 | 0.24 | – | 0.33 | 0.23 | – | – | 0.41 | 0.36 | – | – | – | 0.65 |
| HCV infected | ||||||||||||
| 1 | – | 0.29 | 0.28 | 0.91 | – | – | 0.40 | 0.38 | 0.23 | 0.28 | – | 0.44 |
| 2 | 0.31 | – | – | 0.59 | 0.23 | – | – | – | 0.40 | 0.49 | 0.58 | 0.21 |
| 3 | – | – | – | 1.06 | – | – | 0.33 | 0.27 | – | – | – | 0.60 |
| 4 | – | – | – | 0.93 | 0.30 | – | 0.58 | 0.50 | – | – | – | 0.66 |
| 5 | – | – | – | 0.88 | 0.21 | – | 0.31 | 0.61 | – | – | – | 0.70 |
| 6 | – | – | – | 0.54 | 0.30 | – | 0.24 | 0.29 | 0.30 | 065 | 0.71 | 0.55 |
| 7 | – | 0.21 | – | 1.17 | 0.33 | – | 0.27 | 0.45 | – | – | – | 0.82 |
| 8 | – | – | 0.33 | 1.31 | – | – | 0.60 | 0.23 | – | – | 0.67 | 0.36 |
| 9 | – | – | – | – | – | – | – | 0.21 | 0.22 | – | 0.33 | 0.46 |
| 10 | – | – | – | 0.38 | – | – | 0.33 | 0.48 | 0.39 | – | 0.39 | 0.41 |
| 11 | – | – | – | 0.34 | 0.29 | – | 0.41 | – | – | – | 0.44 | 0.42 |
| 12 | – | – | – | 1.16 | – | – | 0.45 | 0.46 | – | 0.89 | 0.82 | 0.48 |
| 13 | – | – | – | 0.47 | – | – | – | 0.29 | – | – | – | – |
| 14 | – | 0.33 | – | – | – | – | 0.27 | 0.46 | – | – | 0.28 | 0.35 |
| 15 | – | – | – | 0.28 | – | – | 0.33 | 0.51 | 0.27 | – | – | 0.30 |
| 16 | 0.22 | – | – | 1.28 | 0.40 | – | – | 0.90 | 0.46 | 0.60 | 0.83 | 0.34 |
| 17 | 0.26 | – | – | 0.78 | – | – | 0.30 | 0.48 | 0.47 | – | – | 0.79 |
| 18 | – | – | – | 1.19 | 0.48 | – | 0.48 | – | – | 0.58 | 0.23 | 0.34 |
| 19 | – | 0.27 | – | 0.83 | 0.27 | – | 0.38 | – | 0.33 | 0.73 | 0.85 | 0.53 |
| 20 | – | – | 0.23 | 0.42 | 0.50 | – | 0.77 | 0.43 | – | – | – | 0.48 |
| 21 | – | – | – | 0.46 | – | – | 0.38 | 0.33 | 0.21 | – | 0.49 | 0.58 |
| 22 | – | – | – | 0.31 | – | – | 0.44 | – | – | – | 0.58 | 0.77 |
| 23 | 0.23 | – | – | 1.22 | – | – | 0.45 | 0.60 | – | 0.96 | 0.71 | 0.80 |
| 24 | – | – | – | 0.38 | – | – | 0.24 | 0.23 | – | – | – | 0.31 |
| 25 | 0.22 | – | – | 0.43 | – | – | – | 0.39 | – | – | 0.26 | – |
| 26 | – | – | – | 0.26 | – | – | 0.50 | 0.44 | 0.31 | – | – | 0.36 |
| 27 | – | – | – | 1.38 | 0.38 | 0.23 | – | 0.58 | 0.50 | 0.55 | 0.83 | 0.71 |
| 28 | – | – | – | 0.91 | – | – | 0.48 | 0.56 | 0.46 | – | – | 0.88 |
| 29 | – | – | 0.28 | 1.25 | 0.39 | – | 0.52 | – | – | 0.55 | – | – |
Peptide sequence and similarity level to human proteome are detailed under Table 1. Results are expressed as effective absorbance. The absorbance was measured at wavelengths of 450 and 620 nm. The effective absorbance was calculated subtracting A 620 from A 450. Samples were considered to be negative (-) when effective absorbance was ≤0.20. Data are average values of two independent assays